GT Biopharma, Inc. 8-K

What Happened
GT Biopharma, Inc. announced via Form 8-K that on May 20, 2026 Nasdaq’s Listing Qualifications Staff granted the company an additional 180‑calendar‑day compliance period — until November 16, 2026 — to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The company previously received an initial notice on November 20, 2025 after its stock closed below $1.00 for 30 consecutive business days and was given a first compliance period ending May 19, 2026.

Key Details

• Nasdaq letter dated May 20, 2026 extends the deadline to November 16, 2026 (additional 180 days).
• Compliance is achieved if the closing bid price is at least $1.00 for a minimum of 10 consecutive business days (subject to Staff discretion to extend).
• Nasdaq said GT Biopharma meets the market value of publicly held shares and other initial listing requirements except the minimum bid price.
• The company’s common stock par value is $0.001 per share; GT Biopharma will monitor the stock price and evaluate options to regain compliance.

Why It Matters
This extension gives investors a clear timeline (through Nov 16, 2026) to watch for the company to restore its share price above $1.00; failing to meet the requirement could lead to delisting from the Nasdaq Capital Market, which may reduce liquidity and make it harder for the company to access capital. The filing confirms there is no assurance GT Biopharma will regain compliance, so shareholders should monitor trading price trends and company updates.